

H1N1 Influenza Vaccine Development: A Collaborative Process

NIH's Network of Vaccine and Treatment Evaluation Units (VTEUs)



- Established in 1962
- >160 Phase I, II, and III clinical trials since 1995
- Trials of vaccines, antivirals
- $189M over 7 years, avg $27M/yr (FY08-FY14)

NIAID Clinical Trials for 2009 H1N1 Vaccine

- Dosage (15 versus 30 micrograms) and number of doses
- Different age groups - children, adults, elderly
- Special groups - pregnant women
- Timing of administration of seasonal flu and 2009 H1N1 flu vaccines
- Adjuvants
- HIV-infected individuals
- Asthmatics

Vaccines: Risks versus Benefits